Corporation, AmerisourceBergen Drug Corporation, and Cardinal Health Inc. Strategy The company’s strategy is to capitalize on growth from its five key commercial products; continue to advance its pipeline; and improve revenues and strategically invest in its late-stage pipeline. Its business strategy includes forming collaborations to develop and commercialize its products, and in so doing, access technological, financial, marketing, manufacturing, and other resources. Research and Development The company’s research and development efforts include areas, such as pharmaceutical formulation, analytical chemistry, process development, engineering, scale-up, and drug optimization/delivery. Patents and Proprietary Rights The company has filed various patent applications in the U.S. and in other countries directed to compositions of matter, as well as processes of preparation and methods of use, including applications relating to each of its delivery technologies. It owns approximately 200 issued U.S. patents. The latest of the patents covering AMPYRA/FAMPYRA, which incorporates its Oral Controlled Release technology, expires in 2027 in the U.S. and 2025 in Europe. The latest of the patents covering INVEGA SUSTENNA expires in 2019 in the U.S. and 2018 in the EU. The latest of its patents covering VIVITROL, RISPERDAL CONSTA and BYDUREON expire in 2029, 2023 and 2025 in the U.S., respectively, and 2021, 2021 and 2024 in Europe, respectively. The company’s trademark, VIVITROL, is primary to the company and is covered by trademark applications or registrations in the U.S. Patent and Trademark Office and the patent or trademark offices of other countries. Its partnered products also use trademarks that are owned by its partners, such as the marks, RISPERDAL CONSTA and INVEGA SUSTENNA, which are registered trademarks of Johnson & Johnson Corp.; BYDUREON, which is a trademark of Amylin; and AMPYRA and FAMPYRA, which are registered trademarks of Acorda. Regulatory Under the Veterans Health Care Act of 1992, the company is required to offer discounted Federal Supply Schedule contract pricing to four federal agencies, such as the Department of Veterans Affairs; the Department of Defense; the Coast Guard; and the Public Health Services (including the Indian Health Service)—for federal funding to be made available for reimbursement of any of the company’s products by such federal agencies and certain federal grantees. The company is subject to the U.S. Foreign Corrupt Practices Act, which prohibits the U.S. corporations and their representatives from paying, offering to pay, promising, authorizing, or making payments of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The company is also subject to the UK Bribery Act, which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official, and failing to have adequate procedures to prevent employees and other agents from giving bribes. The company is subject to various financial disclosure and securities trading regulations as a public company in the U.S., including laws relating to the oversight activities of the Securities and Exchange Commission and the regulations of the NASDAQ, on which its shares are traded. Competition In the treatment of alcohol dependence, VIVITROL competes with CAMPRAL (acamprosate calcium) sold by Forest Laboratories and ANTABUSE sold by Odyssey Pharmaceuticals. In the treatment of opioid dependence, VIVITROL competes with Reckitt Benckiser Pharmaceuticals, Inc. in the U.S. BYDUREON competes with Novo Nordisk A/S. History Alkermes Public Limited Company was founded in 1987.
alkermes plc (ALKS:NASDAQ GS)
1 Burlington Road
Phone: 353 1 772 8000
|BioMarin Pharmaceutical Inc||$70.16 USD||+0.54|
|Dendreon Corp||$3.01 USD||-0.01|
|Jazz Pharmaceuticals Plc||$117.04 USD||+2.70|
|Lupin Ltd||857.85 INR||0.00|
|Nektar Therapeutics||$11.54 USD||+0.08|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.